Elagolix-003-R-HCl, identified by its CAS number 1150560-46-5, is a synthetic small molecule that functions as a gonadotropin-releasing hormone (GnRH) antagonist. It is primarily used in the treatment of conditions such as endometriosis and uterine fibroids by inhibiting the secretion of gonadotropins, which in turn reduces estrogen production. This mechanism helps alleviate symptoms associated with these conditions. The compound is characterized by its specific binding affinity to GnRH receptors, leading to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels. Elagolix-003-R-HCl is typically administered orally and has been studied for its pharmacokinetics, safety, and efficacy in clinical settings. Its chemical structure includes a unique arrangement of functional groups that contribute to its biological activity and pharmacological profile. As with any medication, potential side effects and contraindications should be considered, and it is essential to consult healthcare professionals for appropriate use.

Elagolix-003-R-HCl

1150560-46-5: Elagolix-003-R-HCl, identified by its CAS number 1150560-46-5, is a synthetic small molecule that functions as a gonadotropin-releasing hormone (GnRH) antagonist. It is primarily used in the treatment of conditions such as endometriosis and uterine fibroids by inhibiting the secretion of gonadotropins, which in turn reduces estrogen production. This mechanism helps alleviate symptoms associated with these conditions. The compound is characterized by its specific binding affinity to GnRH receptors, leading to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels. Elagolix-003-R-HCl is typically administered orally and has been studied for its pharmacokinetics, safety, and efficacy in clinical settings. Its chemical structure includes a unique arrangement of functional groups that contribute to its biological activity and pharmacological profile. As with any medication, potential side effects and contraindications should be considered, and it is essential to consult healthcare professionals for appropriate use.

Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoi

Elagolix Ethyl Ester Hydrochloride (Ethyl (R)-4-{[2-(5-(2-fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl]amino}butanoate hydrochloride)

CAS 1150560-46-5

Elagolix-003-R-HCl

Elagolix Ethyl Ester Hydrochloride (Ethyl (R)-4-{[2-(5-(2-fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl]amino}butanoate hydrochloride)

Ref: 45-1A12420